A pill bottle laying on top of a prescription with white pills spilling out.

POISON ALERT: SULFONYLUREA OVERDOSE TREATMENT

Julie Weber Poison Alerts

Often included in “One Pill Can Kill” lists, sulfonylureas (SU) have the potential for significant toxicity in overdose. These medications were the first orally-active agents to treat Type 2 Diabetes, approved in the late 1950s, but now represent only one class among many newer antidiabetic agents and combination products. The commonly prescribed SUs include glimepiride (Amaryl), glipizide (Glucotrol, Glucotrol XL), and glyburide (DiaBeta).  Of the 1st generation agents, chlorpropamide and tolazamide are off the market, and tolbutamide is rarely prescribed. 

MECHANISM OF ACTION

In short, these medications increase the secretion of insulin in a functioning pancreas. Sulfonylureas bind to receptors on the pancreatic beta cells and block the movement of potassium through ATP-dependent channels.  This in turn increases the flow of calcium into the cells, which triggers the exocytosis of insulin. 

KINETICS

Sulfonylureas are available as immediate-release and extended-release formulations. The peak and duration vary between agents. Risk of recurrent hypoglycemia may persist 24 to 60 hours after sulfonylurea ingestion, depending on the specific agent and the magnitude of the overdose.   

DRUG NAME PEAK HALF-LIFE DURATION
Glimepiride (Amaryl) 2-3 hours            5-9 hours                 24 hours                   
Glipizide IR (Glucotrol)

Glipizide ER (Glucotrol XL)

1-3 hours

6-12 hours

2-5 hours 10-24 hours

24 hours

Glyburide non-micronized (formerly Diabeta)

Glyburide micronized (formerly Micronase, Glynase)

2-4 hours

1 hour

10 hours

4 hours

16-24 hours

12-24 hours

TOXICITY

While the adage “One Pill Can Kill” may be bit overstated and requires more nuance, it is true that less than a single adult therapeutic dose of a sulfonylurea poses a potential risk of hypoglycemia in young children that requires monitoring and treatment. Regardless of age, healthy individuals, who unlike Type 2 diabetics are not protected from insulin action by peripheral insulin resistance, are more sensitive to the drug-induced rise in insulin. 

The risk for drug-induced hypoglycemia is higher in:

  • Children and elderly due to reduced glycogen stores
  • Those with recently-restricted food and/or carbohydrate intake
  • Malnourished individuals
  • Those with hepatic or renal insufficiency

While the primary symptom seen in sulfonylurea poisoning is hypoglycemia, the patient may also experience upset stomach, nausea, and vomiting. Symptoms of hypoglycemia can range from the early adrenergic warning symptoms such as shakiness, diaphoresis, and tachycardia, to critical CNS symptoms that indicate glucose shortage in the brain.

Hypoglycemia                      CNS: Irritability, confusion, difficulty sleeping paraesthesia, loss of coordination, lethargy, syncope, hypothermia, focal neurological signs, seizures, and coma.

Adrenergic: Shakiness, trembling, diaphoresis, cold clamminess, weakness, anxiety, palpitations, and hunger.

Gastrointestinal    Nausea, vomiting, and epigastric pain.
Cardiovascular Sinus tachycardia, atrial fibrillation, and myocardial ischemia are possible during to severe hypoglycemia.
Metabolic Hypoglycemia can be symptomatic and recurrent.

Chlorpropamide can cause hyponatremia due to decreased free water excretion.

MANAGEMENT OF TOXICITY

There are 3 key areas of focus when managing sulfonylurea poisoning: blood glucose, supplemental dextrose, and octreotide. Patients should be allowed food and drink as desired.

DOSING OF IV DEXTROSE

  • Adults: 50 mL IV bolus of 50% dextrose.
  • Children: 0.5 to 1 g/kg IV bolus of 10% dextrose (25% for older children)
  • Concurrently with the bolus, begin IV infusion of 10% dextrose to maintain blood glucose at 90 to 120 mg/dL. Children may need glucose solution at a 15% or higher concentration to avoid fluid overload.

DOSING OF OCTREOTIDE

  • Adults: 50 mcg SQ every 6 to 12 hours; 2 to 3 doses are usually sufficient.
  • Children: 1 mcg/kg SQ or IV. Dose may be titrated upwards or repeated every 6 hours of hypoglycemia recurs. In severe cases, may be administered as IV drip at a rate of 15 ng/kg/minute.
  1. Monitor blood glucose every 1 to 2 hours at the bedside and immediately if hypoglycemic symptoms occur. Depending on the agent, intervals between becks can be increased after the drug peaks and effect starts to decline
  2. Administer IV dextrose bolus if blood glucose falls below 60 mg/dL or if patient develops symptomatic hypoglycemia. A continuous infusion is recommended to keep blood glucose between 90-120 mg/dL. IMPORTANT: Do not prophylactically give IV dextrose as it can precipitate hypoglycemia and confuse the clinical picture.
  3. Octreotide, a synthetic analog of somatostatin, is the antidote to sulfonylurea action because it inhibits insulin release from the pancreas. This medicine is indicated after the first episode of sulfonylurea-induced hypoglycemia that requires treatment with a glucose bolus. Monitor for recurrent hypoglycemia for 12-24 hours after octreotide is discontinued.

OBSERVATION

Asymptomatic children and non-diabetic adults with accidental ingestion or suspected ingestion should be observed for at least 12 hours. If discharging to home, hold patient until the daytime when they can eat freely. The long overnight fasting during sleep poses a significant risk of hypoglycemia if the drug is still present.

Sulfonylurea toxicity can be dangerous if hypoglycemia occurs. Our advice is to call the Missouri Poison Center at 1-800-222-1222 where specially trained nurses, pharmacists, and medical toxicologists can provide you with the most up-to-date management advice on common and uncommon exposures.

print

Share this Post